Den europeiske union - maltesisk - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatide - l-osteoporożi - homeostasi tal-kalċju - qutavina is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Den europeiske union - portugisisk - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatida - osteoporosis; osteoporosis, postmenopausal - homeostase de cálcio - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

viatris healthcare limited - teriparatide - teriparatide

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

teva sweden ab - teriparatid (syntetisk) - injektionsvätska, lösning i förfylld injektionspenna - 20 mikrogram/80 mikroliter - mannitol hjälpämne; teriparatid (syntetisk) 0,25 mg aktiv substans

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

2care4 aps - teriparatid (syntetisk) - injektionsvätska, lösning i förfylld injektionspenna - 20 mikrogram/80 mikroliter - teriparatid (syntetisk) 0,25 mg aktiv substans; mannitol hjälpämne

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

welding gmbh & co. kg - tériparatide - solution - 600 microgrammes - composition pour un stylo prérempli de 2,4 ml > tériparatide : 600 microgrammes - homéostasie du calcium, hormones parathyroïdiennes et analogues

Israel - engelsk - Ministry of Health

dexcel ltd, israel - teriparatide - solution for injection - teriparatide 250 mcg/ml - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture: terrosa is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis,terrosa increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture: terrosa is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture: terrosa is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - teriparatide, quantity: 250 microgram - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate; hydrochloric acid; mannitol; sodium hydroxide; water for injections; metacresol - forteo is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures. forteo is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - teriparatide 0.25 mg/ml (as acetate) - solution for injection - 250 mcg/ml - active: teriparatide 0.25 mg/ml (as acetate) excipient: glacial acetic acid hydrochloric acid mannitol metacresol nitrogen sodium acetate sodium hydroxide water for injection - teriparatide bnm is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

Israel - hebraisk - Ministry of Health

eli lilly israel ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 250 mcg/ml - teriparatide - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, forteo increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:forteo is indicated for the treatment of men and women with osteopo